english.prescrire.org > Prescrire International > N°165 - November 2015

n°165

November 2015

Issue Contents
Editorial

Free  Adverse effect reporting: pharmaceutical companies can't be trusted

p.256
It is unacceptable that regulators rely on the drug industry to develop pharmacovigilance

Marketing Authorisations

Telavancin (Vibativ°)

p.257-259
A vancomycin derivative, no more effective but more toxic

Ceftobiprole medocaril (Mabelio°)

p.260-261
Just another injectable cephalosporin

Ofatumumab in previously untreated chronic lymphocytic leukaemia

p.262-263
No clear advantages when added to chlorambucil

Free  Ivabradine: more precautions to protect patients with coronary artery disease because of its cardiac harms

p.264

Riociguat (Adempas°)

p.265-266
Chronic thromboembolic pulmonary hypertension with markedly restricted physical activity

INN common stem: -bulin

p.266

Adverse Effects

Atypical neuroleptics in elderly patients: acute kidney injury

p.267
Within 90 days after treatment initiation

Rivaroxaban: liver injury

p.268
Hundreds of reports

Mydriatic eye drops in children: seizures

p.268
Dose-dependent

Capecitabine: toxic encephalopathy

p.269
Regress after discontinuation

Betahistine: hallucinations?

p.269
This drug should not be used

Sorafenib: osteonecrosis of the jaw

p.269
Dental treatment is a risk factor

NSAIDs: impaired healing of intestinal anastomoses

p.269-270
Mainly reported in non-elective colorectal surgery

High-dose intravenous methylprednisolone: liver injury

p.270
Potentially fatal

Diphenhydramine, dimenhydrinate: misuse

p.270
Stimulating, euphoriant effects

Aripiprazole: violent behaviour

p.270
Patients and carers should be informed

Reviews

E-cigarettes and smoking cessation

p.271-276
Similar efficacy to other nicotine delivery devices, but many uncertainties

Inhibiting the onset of lactation

p.276-277
Is cabergoline an alternative to bromocriptine?

Outlook

Free  Obstacles to transparency over pharmacovigilance data within the EMA

p.278-279
Action is needed to ensure access to adverse effects

Pay for performance: financial rewards without improving quality of care

p.279
The example of benzodiazepine use

Masthead

Free  Masthead

p.254

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe